Proprietary Oral-film TechnologyKlaria’s mucoadhesive oral‑film platform is a structural competitive asset: it enables differentiated drug delivery and potential IP protection. Over months this supports licensing interest, product differentiation versus alternatives, and a pathway to recurring partner revenues if clinical progress continues.

Partnering/licensing StrategyA stated strategy to pursue partnering and licensing reduces capital intensity and execution burden versus full commercialization. Structurally, this model can accelerate revenue realization through milestone and royalty streams while shifting commercialization risk to partners, preserving cash.

Debt Reduction In 2025Reported elimination of debt by 2025 materially lowers interest and bankruptcy risk, improving near‑term financial flexibility. This structural de‑leveraging increases optionality for funding R&D, negotiating partnerships, or conducting equity raises without heavy debt service constraints.

Bears Say

Negative EquityStockholders’ equity turning negative is a durable solvency concern: it signals accumulated losses or dilution that weakens creditor confidence and reduces borrowing capacity. Over 2–6 months this constrains financing options and could force dilutive raises or unfavorable partner terms.

Persistent Cash BurnOperating cash flow has been negative across reported years, with a sharp -35M outflow in 2025. This structural cash burn necessitates external financing to sustain operations and R&D, increasing dilution risk and making long‑term program continuity dependent on successful partnering or capital markets access.

Large Operating LossesThe company reports persistent, substantial losses (2025 net margin ~-432%), indicating R&D and revenues have not yielded scalable economics. This structural unprofitability pressures runway and strategic flexibility, requiring either meaningful commercial success, licensing deals, or regular external funding to continue operations.

KLAR FAQ

What was Klaria Pharma Holding AB’s price range in the past 12 months?

Klaria Pharma Holding AB lowest stock price was kr0.39 and its highest was kr1.66 in the past 12 months.

What is Klaria Pharma Holding AB’s market cap?

Klaria Pharma Holding AB’s market cap is kr196.78M.

When is Klaria Pharma Holding AB’s upcoming earnings report date?

Klaria Pharma Holding AB’s upcoming earnings report date is May 08, 2026 which is in 59 days.

How were Klaria Pharma Holding AB’s earnings last quarter?

Klaria Pharma Holding AB released its earnings results on Feb 20, 2026. The company reported -kr0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.034.

Is Klaria Pharma Holding AB overvalued?

According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Klaria Pharma Holding AB pay dividends?

Klaria Pharma Holding AB does not currently pay dividends.

What is Klaria Pharma Holding AB’s EPS estimate?

Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Klaria Pharma Holding AB have?

Klaria Pharma Holding AB has 245,976,150 shares outstanding.

What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?

Klaria Pharma Holding AB reported an EPS of -kr0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.809%.

Which hedge fund is a major shareholder of Klaria Pharma Holding AB?

Currently, no hedge funds are holding shares in SE:KLAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Klaria Pharma Holding AB

Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.